Cefuroxime and Potassium Clavulanic Acid Tablets
Cefuroxime and Potassium Clavulanic Acid Tablets – PULMOTOP – CV 500 ® is the combination of the two drugs that are Cefuroxime and Potassium Clavulanic Acid that is used to treat bacterial infections. Cefuroxime is a type of medicine that fights bacteria. It works by stopping bacteria from making a shield that helps them survive in the human body. Clavulanic Acid is a substance that stops certain bacteria from using enzymes to break down Cefuroxime, making the medicine more effective. Adding Clavulanic Acid helps overcome bacteria resistance and makes Cefuroxime more effective against bacteria.
Cefuroxime and Potassium Clavulanic Acid tablets are used to treat bacterial infections. Here are the detailed uses of the medicines are given below:
Before using this medicine, let your doctor know if you are taking any other medicines for your health. Pregnant or nursing women should talk to their doctor before taking it. Don’t drink alcohol because it can make you very sleepy when you take this medicine. It usually doesn’t affect your driving, but you shouldn’t drive if it makes you feel sleepy or dizzy. You should get enough rest to heal faster, eat healthy food, and drink lots of water. Your doctor might ask for some tests to see how the medicine is affecting your body.
Cefuroxime and Potassium Clavulanic Acid Tablets is a medicine you need a doctor’s prescription to get. It is recommended to take it according to the doctor’s instructions. You can take it with or without food, but try to take it at the same time every day for it to work better. Don’t take more than the suggested amount, as it could be bad for your body. If you forget to take a dose, take it as soon as you can remember. You need to finish the treatment even if you start feeling better. Stopping the treatment suddenly might make the medicine less effective.
Here are the common side effects of the Cefuroxime and Potassium Clavulanic Acid tablets:
Pack | 10 X 1 X 10 ( Alu Alu) |
---|
Reviews
There are no reviews yet.